transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2016-3-3-67-72transmed-191Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHПовышение уровня интерлейкина-6 перед радиочастотной аблацией легочных вен увеличивает риск рецидива через шесть месяцев у пациентов с пароксизмальной фибрилляцией предсердийElevated level of interleukin-6 before radiofrequency ablation of pulmonary vein increases the risk of relapse after six months in patients with paroxysmal atrial fibrillationКорнелюкОксана МихайловнаKarnialiukOksana M.kornella_oks@tut.byРеспубликанский научно-практический центр «Кардиология»РоссияScientific and Practical center of CardiologyRussian Federation201623122016336772Copyright © Корнелюк О.М., 20162016Корнелюк О.М.Karnialiuk O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/191

Уровень интерлейкина-6 до радиочастотной аблации легочный вен более 1,77 мкмоль/л увеличивает риск рецидива через шесть месяцев у пациентов с пароксизмальной фибрилляцией предсердий.

The level of IL-6 more than 1.77 mmol / L before the radiofrequency ablation of pulmonary veins increases the risk of recurrence after six months in patients with paroxysmal atrial fibrillation.

фибрилляция предсердийрадиочастотная аблацияинтерлейкин-6пороговое значениеatrial fibrillationradiofrequency ablationinterleukin - 6thresholdReferencesKobza R., Hindricks G., Tanner H., Schirdewahn P., Dorszewski A., Piorkowski C., Gerds-Li J.H., Kottkamp H. Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment. Heart Rhythm. 2004;1(6): 676-683.Kobza R., Hindricks G., Tanner H., Schirdewahn P., Dorszewski A., Piorkowski C., Gerds-Li J.H., Kottkamp H. Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment. Heart Rhythm. 2004;1(6): 676-683.Nilsson B., Chen X., Pehrson S., Kөber L., Hilden J., Svendsen J.H. Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy. Am Heart J. 2006; 152(3): 537. e1-8.Nilsson B., Chen X., Pehrson S., Kөber L., Hilden J., Svendsen J.H. Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy. Am Heart J. 2006; 152(3): 537. e1-8.Rostock T., Rotter M., Sanders P., Takahashi Y., Jaïs P., Hocini M., Hsu L.F., Sacher F., Clémenty J., Haïssaguerre M. High-density activation mapping of fractionated electrograms in the atria of patients with paroxysmal atrial fibrillation. Heart Rhythm. 2006;3(1): 27-34.Rostock T., Rotter M., Sanders P., Takahashi Y., Jaïs P., Hocini M., Hsu L.F., Sacher F., Clémenty J., Haïssaguerre M. High-density activation mapping of fractionated electrograms in the atria of patients with paroxysmal atrial fibrillation. Heart Rhythm. 2006;3(1): 27-34.Pokushalov E., Romanov A., De Melis M., Artyomenko S., Baranova V., Losik D., Bairamova S., Karaskov A., Mittal S., Steinberg JS. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation. Circ Arrhythm Electrophysiol. 2013; 6(4): 754-760.Pokushalov E., Romanov A., De Melis M., Artyomenko S., Baranova V., Losik D., Bairamova S., Karaskov A., Mittal S., Steinberg JS. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation. Circ Arrhythm Electrophysiol. 2013; 6(4): 754-760.Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., Hindricks G., Kirchhof P.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21): 2719-2147.Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., Hindricks G., Kirchhof P.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21): 2719-2147.Calkins H., et al. Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012; 9(4): 632-696.e21.Calkins H., et al. Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012; 9(4): 632-696.e21.Kaitani K., et al, EAST-AF Trial Investigators. Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial. Eur Heart J. 2016;37(7): 610-618.Kaitani K., et al, EAST-AF Trial Investigators. Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial. Eur Heart J. 2016;37(7): 610-618.Hatzinikolaou-Kotsakou E., Tziakas D., Hotidis A., Stakos D., Floros D., Papanas N., Chalikias G., Maltezos E., Hatseras D.I. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol. 2006;97(5): 659-661.Hatzinikolaou-Kotsakou E., Tziakas D., Hotidis A., Stakos D., Floros D., Papanas N., Chalikias G., Maltezos E., Hatseras D.I. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol. 2006;97(5): 659-661.den Uijl D.W., Delgado V., Tops L.F., Ng A.C., Boersma E., Trines S.A., Zeppenfeld K., Schalij M.J., van der Laarse A., Bax J.J. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J. 2011;161(1): 197-203.den Uijl D.W., Delgado V., Tops L.F., Ng A.C., Boersma E., Trines S.A., Zeppenfeld K., Schalij M.J., van der Laarse A., Bax J.J. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J. 2011;161(1): 197-203.Rossi A., Enriquez-Sarano M., Burnett J.C. Jr., Lerman A., Abel M.D., Seward J.B. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000;35(5): 1256-1262.Rossi A., Enriquez-Sarano M., Burnett J.C. Jr., Lerman A., Abel M.D., Seward J.B. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000;35(5): 1256-1262.Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20): 1475-1480.Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20): 1475-1480.Leftheriotis D.I., Fountoulaki K.T., Flevari P.G., Parissis J.T., Panou F.K., Andreadou I.T., Venetsanou K.S., Iliodromitis E.K., Kremastinos D.T. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol. 2009;135(3): 361-369.Leftheriotis D.I., Fountoulaki K.T., Flevari P.G., Parissis J.T., Panou F.K., Andreadou I.T., Venetsanou K.S., Iliodromitis E.K., Kremastinos D.T. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol. 2009;135(3): 361-369.Henningsen K.M., Therkelsen S.K., Bruunsgaard H., Krabbe K.S., Pedersen B.K., Svendsen J.H. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest. 2009;69(3): 425-432.Henningsen K.M., Therkelsen S.K., Bruunsgaard H., Krabbe K.S., Pedersen B.K., Svendsen J.H. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest. 2009;69(3): 425-432.Henningsen K.M., Nilsson B., Bruunsgaard H., Chen X., Pedersen B.K., Svendsen J.H. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand Cardiovasc J. 2009;43(5): 285-291.Henningsen K.M., Nilsson B., Bruunsgaard H., Chen X., Pedersen B.K., Svendsen J.H. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand Cardiovasc J. 2009;43(5): 285-291.Liu T., Li G., Li L., Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a metaanalysis. J Am Coll Cardiol. 2007;49(15): 1642-1648.Liu T., Li G., Li L., Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a metaanalysis. J Am Coll Cardiol. 2007;49(15): 1642-1648.

The authors declare that there are no conflicts of interest present.